Robert Doucet

About

Dr. Robert Doucet is a leading radiation oncologist whose research centers on stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC), with a particular focus on robotic delivery systems like CyberKnife. His major contributions include demonstrating excellent cancer outcomes through patient-adapted robotic lung SBRT, achieving high local control rates while carefully managing toxicity. Notably, his 2014 study (33 citations) established a critical caution: while outcomes are excellent for most patients, those with idiopathic pulmonary fibrosis face significantly elevated risks, guiding safer treatment protocols. Dr. Doucet has also pioneered the investigation of long-term quality of life in NSCLC survivors treated with robotic stereotactic ablative radiation therapy (24 citations), showing that patients maintain favorable functional outcomes years after treatment. His comparative work (21 citations) between CyberKnife and conventional SBRT has clarified patterns of local control and distant metastasis, helping clinicians choose optimal delivery methods. Through these studies, Dr. Doucet has shaped modern lung SBRT practice, balancing curative intent with patient safety and quality of life considerations.

Research Focus

Key Achievements

Top Papers

1. 1
   Excellent Cancer Outcomes Following Patient-adapted Robotic Lung SBRT But a Case for Caution in Idiopathic Pulmonary Fibrosis

   33 citations · 2014
2. 2
   Long-term quality of life in early-stage non-small cell lung cancer patients treated with robotic stereotactic ablative radiation therapy

   24 citations · 2015
3. 3
   Comparing local control and distant metastasis in NSCLC patients between CyberKnife and conventional SBRT

   21 citations · 2020

Key Collaborators

Contact & Links